Synopsis : Sun Pharma has announced one of India’s largest outbound deals, acquiring Organon in an all-cash transaction. The move strengthens its global footprint and expands its women’s health and specialty portfolio.
Sun Pharmaceutical Industries has announced a landmark acquisition of Organon & Co in an all-cash deal valued at $11.75 billion, including debt, marking one of the biggest overseas acquisitions by an Indian drugmaker.
Under the agreement, Sun Pharma will acquire all outstanding shares of Organon at $14 per share, representing a premium of over 24% to its last closing price. The deal highlights Sun Pharma’s aggressive push to expand its global presence and diversify its product portfolio.
Organon, which was spun off from Merck & Co in 2021, brings with it a strong portfolio of over 70 products across women’s health and general medicines, with a presence in more than 140 countries. This acquisition is expected to significantly enhance Sun Pharma’s position in the global women’s healthcare segment.
Strategically, the deal also allows Sun Pharma to strengthen its innovative medicines pipeline and expand into biosimilars—an area of growing importance in the pharmaceutical industry. The combined capabilities and global reach of both companies are expected to create a more diversified and competitive platform.
Financially, Organon carries a debt of $8.6 billion as of December 2025 and recently reported a 5% decline in quarterly revenue along with a net loss of $205 million. Despite these challenges, Sun Pharma sees long-term value in integrating Organon’s portfolio and leveraging its market access.
Sun Pharma plans to fund the acquisition through a mix of internal cash reserves and committed bank financing. The company, currently valued at over $40 billion, has been actively focusing on strengthening its presence in key therapeutic areas such as dermatology, oncology, and obesity treatment.
The move also comes at a time when Sun Pharma is facing pressure in the US market due to pricing challenges and evolving trade policies. Expanding its global footprint and diversifying revenue streams through this acquisition could help mitigate these risks.
Overall, the acquisition marks a significant strategic shift for Sun Pharma, positioning it as a stronger global player with enhanced capabilities in both specialty and general medicine segments.
Disclaimer : This article is for informational purposes only and does not constitute financial or investment advice.
.jpg)